News for AnaptysBio, Inc. (0HFQ.L)

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 350 points on Monday. The Dow traded up 1.35% to 42,551.10 while ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. ( ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology the

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Monday. Shares of Intuitive Machines, Inc. LUNR rose sharply during Monday's ses...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Thursday. Shares of UiPath Inc. PATH fell sharply in today's pre-market...

Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a new chief executive officer. The company said its boa...

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA re

**media[552860]**

**media[552854]**

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently expanded its holdings in Eton Pharmaceuticals Inc by acquiring an additional 583,3

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Aadi Bioscience Inc. On December 31,

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc. GILD rose sharply during Wednesday's s...

AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, Wednesday announced positive data from Phase 2b RENOIR study of rosnilimab for the treatment of rheumatoid arthritis (RA).

Virginia-based Spire Global, Inc. (SPIR) is down over 52 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statist

**media[538162]**

PR NewswireWASHINGTON and SAN DIEGO, Feb. 3, 2025 Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda